Pharmacological actions of anifrolumab (Saphnelo<sup>®</sup>) and clinical trial results as a treatment for systemic lupus erythematosus

DOI Web Site PubMed 51 References

Bibliographic Information

Other Title
  • アニフロルマブ（サフネロー<sup>®</sup>点滴静注300 mg）の薬理学的特徴および全身性エリテマトーデスに対する臨床試験成績

Abstract

<p>Systemic lupus erythematosus (SLE) is an autoimmune disease which causes damaging inflammation in multiple organs via the accumulation of immune complexes. SLE pathogenesis is associated with type I interferons (IFNs), which are central and reflective of disease activity in SLE. Even before clinical development of disease, genetic and environmental contributions to IFN production lead to abnormal innate and adaptive immune activation. Through the Janus kinase-signal transducer and activator of transcription signaling pathway, IFN play a central role in the immunopathogenicity of SLE. Thus, IFN-blocking therapy may be used to regulate inflammation in individuals with SLE. Food and Drug Administration (FDA)-approved anifrolumab (Saphnelo®), which is a human IgG1κ monoclonal antibody that binds to subunit 1 of the type I interferon receptor with high specificity and affinity, was also approved for the treatment of adult patients with moderate to severe SLE who are receiving standard therapy by Pharmaceuticals and Medical Device Agency (PMDA), in Japan in September 2021; anifrolumab is administered as an intravenous infusion, 300 mg over a 30-minute period, every 4 weeks. In this article, we reviewed the actions of type I IFN and anifrolumab as a treatment for SLE.</p>

Journal

References(51)*help

See more

Keywords

Details 詳細情報について

Report a problem

Back to top